Market reaction to FTC's extended review of Catalent acquisition | Categorical | | | 8 months ago | |
FTC decision on Novo Holdings' acquisition of Catalent by end of 2024 | Categorical | | | 8 months ago | |
Further FTC extension on Novo Holdings' acquisition of Catalent review beyond initial 30 days | Binary | | | 8 months ago | |
FTC approval of Novo Holdings' acquisition of Catalent by end of 2024 | Binary | | | 8 months ago | |
FTC requires divestitures for Catalent acquisition approval by 2024 | Binary | | | 8 months ago | |
Novo Nordisk boosts Wegovy and Ozempic production by 30% by mid-2025? | Binary | | | 7 days ago | |
What will be Novo Nordisk's revenue growth rate for 2025? | Categorical | | | 9 days ago | |
Will Novo Nordisk boost Wegovy and Ozempic production by 20% by mid-2025? | Binary | | | 9 days ago | |
What will be Novo Nordisk's market share in anti-obesity drugs by 2025 end? | Categorical | | | 9 days ago | |
How much will Asceneuron raise in its next major funding round by the end of 2025? | Categorical | | | 5 months ago | |
Will Asceneuron announce a partnership with a major pharmaceutical company by the end of 2024? | Binary | | | 5 months ago | |
Impact on Novo Holdings' stock price following FTC decision on Catalent acquisition | Categorical | | | 8 months ago | |
Impact of Catalent acquisition on Novo Nordisk's diabetes market share by end of 2025? | Categorical | | | 7 days ago | |
Novo Nordisk's global pharma revenue rank by end of 2025? | Categorical | | | 7 days ago | |
Novo Nordisk's stock vs. pharma indices performance by end of 2025? | Categorical | | | 7 days ago | |
Novo Nordisk's Odense facility operational by end of 2025? | Binary | | | 7 days ago | |
Novo Nordisk integrates Catalent's capabilities by end of 2025? | Binary | | | 7 days ago | |
What will cause a delay in Catalent acquisition finalization by 2024 end? | Categorical | | | 9 days ago | |
Will Novo Nordisk integrate Catalent's sites by end of 2025? | Binary | | | 9 days ago | |
Will Novo Nordisk face legal challenges over Catalent deal by mid-2025? | Binary | | | 9 days ago | |
Novo Nordisk's market share change post-Catalent acquisition by 2025 | Categorical | | | 9 days ago | |
Will Novo Nordisk integrate Catalent sites by end of 2025? | Binary | | | 9 days ago | |
Will Novo Nordisk launch a product using Catalent sites by end of 2025? | Binary | | | 9 days ago | |
Will Novo Nordisk face regulatory issues from Catalent acquisition by 2025? | Binary | | | 9 days ago | |
Novo Nordisk's revenue growth impact from Catalent acquisition in FY 2025 | Categorical | | | 9 days ago | |
Novo Nordisk's global ranking in pharma sector post-Catalent acquisition by 2025 | Categorical | | | 9 days ago | |
Will Asceneuron successfully complete Phase 2 clinical trials for ASN51 by the end of 2025? | Binary | | | 5 months ago | |
What will be the regulatory approval status of Asceneuron's ASN51 in the EU by the end of 2026? | Categorical | | | 5 months ago | |
What will be the outcome of Asceneuron's Phase 2 clinical trials for ASN51 by the end of 2025? | Categorical | | | 5 months ago | |
Will Asceneuron's ASN51 receive Fast Track designation from the FDA by the end of 2024? | Binary | | | 5 months ago | |
